基于功能化溶胶-凝胶膜的乳腺癌抗原免疫传感器

结合溶胶-凝胶(sol-gel)和交联技术,将乳腺癌抗体固定在铂盘电极表面的氨基化sol-gel功能膜上,制备出用于检测乳腺癌抗原(CA15-3)的免疫传感器.用红外光谱验证了该传感器功能膜的形成过程和组成结构,采用循环伏安法对传感器逐层修饰过程进行了表征,并对传感器功能膜的作用机理进行了探讨.该法检测CA15-3的线性范围为8～240U/mL,线性回归方程为ΔE=75.75lgc-56.36,r=0.998.结果表明,该方法很好地保持了被固定抗体的活性,增强了传感器的稳定性,所制备的传感器于4℃干态保存30d,其响应信号基本不变.且该传感器响应迅速、灵敏度高、选择性好,血清中常见抗原不干扰测定.     

溶胶-凝胶-HBsAb膜免疫传感器的研制与应用

采用溶胶-凝胶(Sol-gel)技术,成功地将乙肝表面抗体(HBsAb)包埋于Sol-gel中,再滴涂于铂盘电极表面,制成溶胶-凝胶-HBsAb膜非标记免疫传感器.根据抗原与抗体特异性结合形成的免疫复合物使敏感膜有效扩散截面积减小的特性,提出了利用铁氰化钾作为氧化还原探针间接检测乙肝表面抗原(HBsAg)的新方法.用循环伏安法(CV)对电极逐层修饰过程进行了表征,并探讨了对HBsAg定量检测的可行性及其响应机理.采用差示脉冲伏安法(DPV)检测人体血清中的HBsAg.线性范围5～320μg/L,线性相关系数r=0.997.该传感器响应迅速,灵敏度高,稳定性好.于4℃干态保存14d,其响应信号基本不变.将其用于108例临床血清检验,与酶联免疫吸附法(ELISA)的符合率为87.5％.     

活化高分子膜免疫电极检测乳腺癌抗原

报道了一种灵敏度高和使用简便的免疫电极,用于测定乳腺癌抗原（CA15－3）。CA15－3抗体固定在用羟胺活化的聚氯乙烯（PVC）－牛血清白蛋白（BSA）基体膜上。当抗体膜与CA15－3血清结合形成抗原体复合物膜后,将该复合物膜固定在自制Ag-AgCI基体电极顶端,利用毫伏计测定膜电位。该法可在15－240U／mL范围测定CA15－3,线性关系良好,回归方程：△E=-8、84 13、97Ig[CA15-3],相关系数0．9998。人血清中其他常见抗原对CA15－3测定基本无干扰。同时,探讨了免疫膜的电位响应机理。     

新型多壁碳纳米管/白藜芦醇印迹溶胶-凝胶层层组装电化学传感器研究

采用电化学沉积方法将印迹溶胶-凝胶膜沉积到功能化碳纳米管(MWNT-COOH)修饰的碳电极表面,成功研制一种新型多壁碳纳米管/白藜芦醇印迹溶胶-凝胶电化学传感器.采用扫描电镜(SEM),循环伏安法(CV),方波伏安法(SWV)和计时电流法(i-t)详细考察该印迹溶胶-凝胶膜的形态和电化学性能.结果表明该传感器对白藜芦醇具有较高的选择性和亲和性.与无多壁碳纳米管修饰的印迹传感器比较,MWNT层修饰的印迹传感器电流响应信号明显提高.白藜芦醇与印迹溶胶-凝胶膜的特异性结合使该传感器的电流发生变化,电流变化与白藜芦醇浓度在5.0×10-7～8.0×10-5mol?L-1范围内呈良好线性关系,检测限为5.1×10-8mol?L-1,该传感器成功应用于葡萄酒中白藜芦醇含量的检测.     

自组装碳纳米管-氯洁霉素分子印迹溶胶-凝胶电化学传感器研究

结合自组装技术, 采用电聚合方法在碳纳米管修饰金电极表面制备对氯洁霉素具有特异性识别位点的分子印迹溶胶-凝胶薄膜, 成功构建了一种新型印迹溶胶-凝胶电化学传感器. 通过循环伏安法(CV)、示差脉冲法(DPV)、安培计时法(I-t)和扫描电镜(SEM)表征了该印迹溶胶-凝胶膜的电化学性能和表面形貌. 结果表明, 该传感器具有良好的选择性和灵敏度, 氯洁霉素在多壁碳纳米管修饰的印迹溶胶-凝胶传感器上的响应明显提高. 该印迹溶胶-凝胶传感器对氯洁霉素的浓度响应线性范围为5.0×10^-7~8.0×10^-5 mol/L, 检出限为2.44×10^-8 mol/L. 该传感器被成功地用于人体尿液中氯洁霉素的分析测定.     

掺杂纳米普鲁士蓝溶胶-凝胶修饰葡萄糖生物传感器

采用溶胶-凝胶法制备了纳米普鲁士蓝微粒,将含纳米普鲁士蓝微粒的TiO2溶胶-凝胶固定在玻碳电极表面得到纳米普鲁士蓝修饰电极,该电极对H2O2产生灵敏的响应,线性范围为0．5～400μmoL／L,较常规普鲁士蓝修饰电极(线性范围为25～500μmol／L)灵敏。电极表面再用溶胶．凝胶法固定葡萄糖氧化酶后构建了葡萄糖生物传感器,响应范围0～20mmoL／L,葡萄糖氧化酶表观米氏常数为8．04mmoL／L。实验表明,该法适合于批量制作高灵敏和高重现性的生物传感器。     

溶胶-凝胶非标记免疫传感器检测乙肝表面抗原

采用溶胶 凝胶 (sol gel)技术包埋乙肝表面抗体 (HBsAb) ,涂布于金盘电极表面 ,构成sol gel HBsAb/Au非标记免疫传感器 ,用于检测人血清中乙肝表面抗原 (HBsAg)。该传感器对HBsAg的电位响应遵循Nernst方程 ,在 1～ 330 μg/L浓度范围内 ,传感器的电位响应值ΔE与HBsAg浓度C的对数呈线性关系 ,线性回归方程为ΔE =1 8.1 7+79.84lgC。响应时间为 3min。癌胚抗原、甲胎蛋白等对测定无明显影响。对于HBsAg阴性血清 ,电位响应值ΔE <30mV ,而对于阳性血清则ΔE >30mV ,据此 ,作为临床判别的依据。对1 0 0例临床血清分别用传感器和酶联免疫法 (ELISA)进行双盲检验 ,两法的符合率为 86 %。     

改进溶胶-凝胶法固定酶结构剖析及在苯酚光化学传感器中的应用

通过光学显微镜比较了用密闭老化法和浸涂法制备的溶胶凝胶膜的表面状态,从实验上证实了用密闭老化法制备的溶胶凝胶膜不会破裂;并用透射电子显微镜观察了包埋辣根过氧化物酶的溶胶凝胶膜的内部结构.结果表明,酶固定于溶胶凝胶中后,与在溶液中一样,呈均匀分布且不易流失.此敏感膜可用于制备基于化学发光强度减弱的苯酚光化学传感器;用竞争反应的原理讨论了响应机理.     

基于硫堇衍生化自组装膜的丙肝电化学免疫传感器

报道了一种制备电流型免疫传感器的新方法。在金电极表面形成巯基自组装单分子层膜,活化后以共价方式竞争键合硫堇分子和丙肝辣根过氧化酶酶标抗体,制得基于硫堇衍生化自组装膜的丙肝电化学免疫传感器。采用循环伏安法和线性扫描伏安法考察了传感器的组装过程,响应电流的性质,以及传感器对丙肝病毒的响应特性,采用线性扫描伏安法对丙肝抗原进行定量分析,线性范围为3．2—16mg／L;检出限为1．2mg／L;线性相关系数r为0．995。取临床血清进行检测,将结果与临床常用的ELISA法比较,探索了该传感器应用于临床检验的可行性。     

可再生使用的溶胶-凝胶甲胎蛋白免疫传感器

可再生使用的溶胶-凝胶甲胎蛋白免疫传感器;溶胶-凝胶(sol-gel); 免疫传感器; 甲胎蛋白; 再生     

Synthesis,anticancer activity,and molecular docking of new pyrazolo[1,5-a]pyrimidine derivatives

The reaction of 3-aminopyrzoles with dimethylamino-acrylonitrile derivatives was utilized for the production of new functionalized pyrazolopyrimidine compounds 4a-c and 6a-c. The structures of the obtained pyrazolopyrimidines were characterized by the different spectroscopic measurements (IR, NMR, and mass analyses). The DFT quantum chemical calculations were applied to the determination of the HOMO-LUMO energies and Mulliken atomic charges. The investigated derivatives exhibited a low HOMO-LUMO energy gap, ranging from 2.70 to 2.34 eV, 4c and both 4b and 6b, respectively. Furthermore, the anticancer activities of the synthesized compounds have also been investigated against four cancer cells as well as normal cells (WI38). The investigated compounds demonstrated an impressive cytotoxic effect on MCF-7 and Hep-2 cells. On comparison with 5-fluorouracil, pyrazolopyrimidines 6a–c showed promising cytotoxic action against MCF-7 and Hep-2, with IC₅₀ values of 18.31–26.51 and 24.15–27.16 μM, respectively. Molecular docking of the prepared pyrazolopyrimidines 4 and 6 with the crystal structure of the KDM5A protein, obtained from the PDB, revealed the types of the protein's binding sites.     

GeneMCL in microarray analysis

Accurately and reliably identifying the actual number of clusters present with a dataset of gene expression profiles, when no additional information on cluster structure is available, is a problem addressed by few algorithms. GeneMCL transforms microarray analysis data into a graph consisting of nodes connected by edges, where the nodes represent genes, and the edges represent the similarity in expression of those genes, as given by a proximity measurement. This measurement is taken to be the Pearson correlation coefficient combined with a local non-linear rescaling step. The resulting graph is input to the Markov Cluster (MCL) algorithm, which is an elegant, deterministic, non-specific and scalable method, which models stochastic flow through the graph. The algorithm is inherently affected by any cluster structure present, and rapidly decomposes a graph into cohesive clusters. The potential of the GeneMCL algorithm is demonstrated with a 5,730 gene subset (IGS) of the Van't Veer breast cancer database, for which the clusterings are shown to reflect underlying biological mechanisms.     

乳腺癌与血清微量元素关系的分析

经临床、病理、放射或CT检查确诊的22名乳腺癌患者。在放疗前后分析血清中Fe、Zn、Cu、Mn、Se、Cr、Co、Ni的含量。结果显示：1．乳腺癌患者与健康人比较Cu、Ni含量增加，而Fe、Zn含量减少；2．健康人锌与其他元素的比值与乳腺癌患者比较，Fe／Zn上升，而Cu／Zn下降；3．乳腺癌患者放疗后与放疗前比较，Zn、Fe、Se、Co含量降低，而Cu、Ni含量增加，因此放疗时要针对降低元素给予合理的补充。     

Proteomics analysis of human breast milk to assess breast cancer risk

Detection of breast cancer (BC) in young women is challenging because mammography, the most common tool for detecting BC, is not effective on the dense breast tissue characteristic of young women. In addition to the limited means for detecting their BC, young women face a transient increased risk of pregnancy‐associated BC. As a consequence, reproductively active women could benefit significantly from a tool that provides them with accurate risk assessment and early detection of BC. One potential method for detection of BC is biochemical monitoring of proteins and other molecules in bodily fluids such as serum, nipple aspirate, ductal lavage, tear, urine, saliva and breast milk. Of all these fluids, only breast milk provides access to a large volume of breast tissue, in the form of exfoliated epithelial cells, and to the local breast environment, in the form of molecules in the milk. Thus, analysis of breast milk is a non‐invasive method with significant potential for assessing BC risk. Here we analyzed human breast milk by mass spectrometry (MS)‐based proteomics to build a biomarker signature for early detection of BC. Ten milk samples from eight women provided five paired‐groups (cancer versus control) for analysis of dysregulatedproteins: two within woman comparisons (milk from a diseased breast versus a healthy breast of the same woman) and three across women comparisons (milk from a woman with cancer versus a woman without cancer). Despite a wide range in the time between milk donation and cancer diagnosis (cancer diagnosis occurred from 1 month before to 24 months after milk donation), the levels of some proteins differed significantly between cancer and control in several of the five comparison groups. These pilot data are supportive of the idea that molecular analysis of breast milk will identify proteins informative for early detection and accurate assessment of BC risk, and warrant further research. Data are available via ProteomeXchange with identifier PXD007066.     

Design and Synthesis of Novel Thioureas Derived from 4‐(4‐Fluorophenoxy)aniline as Anticancer Agents

A new series of thiourea derivatives were obtained by the reaction of 4‐(4‐fluorophenoxy) aniline with different isothiocyanates. Their chemical structures were confirmed by ultraviolet (UV ), infrared (IR ), nuclear magnetic resonance (NMR ), and mass spectral data and elemental analysis. All the synthesized thiourea derivatives were evaluated for their in vitro cancer activity against the human breast cancer cell lines MCF ‐7 (human breast adenocarcinoma) and SKBr ‐3 (human epithelial breast adenocarcinoma). Most of the derivatives exhibited significant anticancer activity. Especially, compound 3 showed the most potent activity (IC₅₀ 20.1 μM ) against SKBr ‐3 when compared with the drugs 5‐fluorouracil and cisplatin, and, most importantly, it did not affect normal breast epithelial cells (4010).     

基于稳健统计的新鲜乳腺组织拉曼光谱分析

采用便携式拉曼光谱仪对新鲜乳腺正常组织、良性组织和恶性组织进行检测,通过稳健统计方法对拉曼光谱数据进行分析处理,建立乳腺组织拉曼光谱标准图谱,根据标准图谱特征峰归纳3类组织的主要区别和特征.在3类乳腺组织中,正常组织有明显的脂类特征峰(1078,1297,1437,1653,1746 cm-1),而在良性和恶性组织中则出现了较明显的蛋白特征峰(1259,1530,1650 cm-1),正常、良性和恶性组织的主要区别集中在1340和1534 cm-1处,应归属为蛋白和类胡萝卜素,这一结果并不能由经典统计方法得出.基于稳健统计建立的新鲜乳腺组织拉曼光谱标准图谱为构建数学模型来鉴别乳腺病灶的性质奠定了基础.     

Comparative toxicity of [3]ferrocenophane and ferrocene moieties on breast cancer cells

Recent results suggest that [3]ferrocenophane may be an interesting motif in the development of cytotoxic anti-cancer agents. We here report the synthesis of three such compounds based on the 1-[(p-R-phenyl)-phenyl-methylidenyl)]-[3]ferrocenophane skeleton with R = OH, NH₂ and NHC(O)CH₃ substitution on one of the phenyl rings. Cytotoxicity studies show that these compounds are up to four times more powerful against hormone-independent breast cancer cells than their corresponding ferrocene analogs.     

Study on the relationship between intake of trace elements and breast cancer mortality with chemometric methods

Several chemometric methods were employed to survey the interaction among the trace elements and the relationship between the intake of these elements and the breast cancer mortality. It is indicated that there are strong interactions among the trace elements so as to form a dynamic balance; the intake of Cr is the most important factor that could cause the increase of breast cancer mortality; no definite relation can be observed between the intake of Cu and that of Zn. However, either the ratio of the intake of Cu and that of Zn or the intake of Cd could show a certain state of dynamic balance among some of the trace elements. Comparison of the analytical methods reveals that it is important to select a suitable method so as to obtain the most appropriate explanation.     

Application of organometallic chemistry in the formulation of a modern therapeutic drug by Ag nanoparticles green-mediated by Allium to treat the breast cancer

In the recent study, we decided to survey the capacities of metallic nanoparticles formulated by Allium monanthum (AgNPs) as a novel chemotherapeutic drug in the treatment of several types of breast cancers. Characterization of AgNPs was done by UV–Visible Spectroscopy (UV–Vis), Fourier Transformed Infrared Spectroscopy (FT‐IR), Transmission Electron Microscopy (TEM), and Field Emission Scanning Electron Microscopy (FE‐SEM). For investigating the antioxidant properties of AgNO₃, Allium monanthum, and AgNPs, the DPPH test was used in the presence of butylated hydroxytoluene as the positive control. To survey the cytotoxicity and anti-breast cancer effects of AgNO₃, Allium monanthum, and AgNPs, MTT assay was used on the breast adenocarcinoma (MCF7), breast carcinoma (Hs 578Bst), infiltrating ductal cell carcinoma (Hs 319.T), infiltrating lobular carcinoma of breast (UACC-3133), inflammatory carcinoma of the breast (UACC-732), and metastatic carcinoma (MDA-MB-453) cell lines. DPPH test revealed similar antioxidant potentials for Allium monanthum, AgNPs, and butylated hydroxytoluene. Silver nanoparticles had very low cell viability and anti-breast cancer properties dose-dependently against MCF7, Hs 578Bst, Hs 319.T, UACC-3133, UACC-732, and MDA-MB-453 cell lines without any cytotoxicity on the normal cell line. The best result of anti-breast cancer properties of AgNPs against the above cell lines was seen in the case of the UACC-3133 cell line. According to the above findings, the silver nanoparticles containing Allium monanthum aqueous extract can be administrated in humans for the treatment of several types of breast cancer especially breast adenocarcinoma, breast carcinoma, infiltrating ductal cell carcinoma, infiltrating lobular carcinoma of breast, inflammatory carcinoma of the breast, and metastatic carcinoma.